Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis

By sjmartinez • January 8, 2024

Kingston P, Blauvelt A, Strober B, Armstrong AW. Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis. J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165. doi: 10.1177/24755303231201336. Epub 2023 Sep 5. PMID: 38188537; PMCID: PMC10768812.

Tags: Dermatology, deucravacitinib, efficacy, mechanism of action, psoriasis, Publications, review, safety, TYK2, tyrosine kinase

Genome-wide DNA methylation patterns in Daphnia magna are not significantly associated with age

Liu R, Morselli M, Yampolsky LY, Peshkin L, Pellegrini M. Genome-wide DNA methylation patterns in Daphnia magna are not significantly associated with age. Epigenetics Chromatin.[...]

Biological Aging in Combination with Lifestyle Factors in the Blood-Based Methylome: A Biomarker for Colorectal Cancer Susceptibility in African American Women

Jung SY, Pellegrini M, Yu H. Biological Aging in Combination with Lifestyle Factors in the Blood-Based Methylome: A Biomarker for Colorectal Cancer Susceptibility in African[...]

Treatment of Solar Lentigines: A Systematic Review of Clinical Trials

Mardani G, Nasiri MJ, Namazi N, Farshchian M, Abdollahimajd F. Treatment of Solar Lentigines: A Systematic Review of Clinical Trials. J Cosmet Dermatol. 2025 Apr;24(4):e70133.[...]